Wiemer EA - Search Results

1

MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors.

Gits CM, van Kuijk PF, Jonkers MB, Boersma AW, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoef C, Mathijssen RH, den Bakker MA, Verweij J, Sleijfer S, Wiemer EA. Gits CM, et al. Among authors: wiemer ea. Int J Cancer. 2014 Jul 15;135(2):348-61. doi: 10.1002/ijc.28694. Epub 2014 Jan 16. Int J Cancer. 2014. PMID: 24375455

2

Expression in hematological malignancies of a glucocorticoid receptor splice variant that augments glucocorticoid receptor-mediated effects in transfected cells.

de Lange P, Segeren CM, Koper JW, Wiemer E, Sonneveld P, Brinkmann AO, White A, Brogan IJ, de Jong FH, Lamberts SW. de Lange P, et al. Cancer Res. 2001 May 15;61(10):3937-41. Cancer Res. 2001. PMID: 11358809

3

Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump.

Burger H, van Tol H, Boersma AW, Brok M, Wiemer EA, Stoter G, Nooter K. Burger H, et al. Among authors: wiemer ea. Blood. 2004 Nov 1;104(9):2940-2. doi: 10.1182/blood-2004-04-1398. Epub 2004 Jul 13. Blood. 2004. PMID: 15251980 Free article.

4

Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps.

Burger H, van Tol H, Brok M, Wiemer EA, de Bruijn EA, Guetens G, de Boeck G, Sparreboom A, Verweij J, Nooter K. Burger H, et al. Among authors: wiemer ea. Cancer Biol Ther. 2005 Jul;4(7):747-52. doi: 10.4161/cbt.4.7.1826. Epub 2005 Jul 9. Cancer Biol Ther. 2005. PMID: 15970668 Free article.

5

Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes.

Burger H, den Bakker MA, Kros JM, van Tol H, de Bruin AM, Oosterhuis W, van den Ingh HF, van der Harst E, de Schipper HP, Wiemer EA, Nooter K. Burger H, et al. Among authors: wiemer ea. Cancer Biol Ther. 2005 Nov;4(11):1270-4. doi: 10.4161/cbt.4.11.2253. Epub 2005 Nov 18. Cancer Biol Ther. 2005. PMID: 16294026 Free article.

6

Practical aspects of managing gastrointestinal stromal tumors.

Sleijfer S, Seynaeve C, Wiemer E, Verweij J. Sleijfer S, et al. Clin Colorectal Cancer. 2006 Nov;6 Suppl 1:S18-23. doi: 10.3816/ccc.2006.s.003. Clin Colorectal Cancer. 2006. PMID: 17101064 Review.

7

The role of microRNAs in cancer: no small matter.

Wiemer EA. Wiemer EA. Eur J Cancer. 2007 Jul;43(10):1529-44. doi: 10.1016/j.ejca.2007.04.002. Epub 2007 May 24. Eur J Cancer. 2007. PMID: 17531469 Review.

8

Improved insight into resistance mechanisms to imatinib in gastrointestinal stromal tumors: a basis for novel approaches and individualization of treatment.

Sleijfer S, Wiemer E, Seynaeve C, Verweij J. Sleijfer S, et al. Oncologist. 2007 Jun;12(6):719-26. doi: 10.1634/theoncologist.12-6-719. Oncologist. 2007. PMID: 17602061 Free article.

9

Pitfalls of the application of microdialysis in clinical oncology: controversial findings with docetaxel.

Loos WJ, Zamboni WC, Engels FK, de Bruijn P, Lam MH, de Wit R, Verweij J, Wiemer EA. Loos WJ, et al. Among authors: wiemer ea. J Pharm Biomed Anal. 2007 Oct 18;45(2):288-94. doi: 10.1016/j.jpba.2007.07.023. Epub 2007 Jul 26. J Pharm Biomed Anal. 2007. PMID: 17804188

10

Drug Insight: gastrointestinal stromal tumors (GIST)--the solid tumor model for cancer-specific treatment.

Sleijfer S, Wiemer E, Verweij J. Sleijfer S, et al. Nat Clin Pract Oncol. 2008 Feb;5(2):102-11. doi: 10.1038/ncponc1037. Nat Clin Pract Oncol. 2008. PMID: 18235442 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

151 results

Search Page

Filters